Table Graph
      published meta-analysis   sensitivity analysis   studies

Spikevax (Moderna mRNA-1273 COVID-19 vaccine) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias confirmed Covid-19, from 1st dosedetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.05 [0.03; 0.09] 0.05[0.03; 0.09]COVE Moderna/NIH phase 3 (study 301), 202010%28,207NAnot evaluable deathsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.50 [0.02; 14.84] 0.50[0.02; 14.84]COVE Moderna/NIH phase 3 (study 301), 202010%28,207NAnot evaluable vaccine efficacy from randomization (ITT)detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.07 [0.04; 0.11] 0.07[0.04; 0.11]COVE Moderna/NIH phase 3 (study 301), 202010%29,148NAnot evaluable symptomatic Covid-19detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.06 [0.03; 0.11] 0.06[0.03; 0.11]COVE Moderna/NIH phase 3 (study 301), 202010%28,207NAnot evaluable severe COVID-19 occurrencedetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.02 [0.00; 0.27] 0.02[0.00; 0.27]COVE Moderna/NIH phase 3 (study 301), 202010%28,207NAnot evaluable serious adverse eventsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.04 [0.78; 1.40] 1.04[0.78; 1.40]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable adverse eventsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.14 [1.08; 1.20] 1.14[1.08; 1.20]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable appendicitisdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 0.67 [0.11; 3.99] 0.67[0.11; 3.99]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable arthralgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 18.37 [13.54; 24.91] 18.37[13.54; 24.91]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable Bell's palsydetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 3.00 [0.31; 28.83] 3.00[0.31; 28.83]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable hypersensitivity, all termsdetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.41 [1.15; 1.72] 1.41[1.15; 1.72]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable lymphadenopathy, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 1.00[0.06; 15.97]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable musculoskeletal and connective tissue disorders, anydetailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 1.00 [0.06; 15.97] 1.00[0.06; 15.97]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable myalgia, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 27.64 [20.93; 36.50] 27.64[20.93; 36.50]COVE Moderna/NIH phase 3 (study 301), 202010%30,351NAnot evaluable fever, grade 3-4detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 43.29 [17.83; 105.10] 43.29[17.83; 105.10]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable local adverse reaction, any, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 33.74 [31.59; 36.03] 33.74[31.59; 36.03]COVE Moderna/NIH phase 3 (study 301), 202010%29,235NAnot evaluable local adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 15.04 [11.83; 19.12] 15.04[11.83; 19.12]COVE Moderna/NIH phase 3 (study 301), 202010%29,235NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 6.69 [6.35; 7.05] 6.69[6.35; 7.05]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable systemic adverse reaction, grade 3-4, dose 2detailed resultsCOVE Moderna/NIH phase 3 (study 301), 2020 9.50 [8.38; 10.77] 9.50[8.38; 10.77]COVE Moderna/NIH phase 3 (study 301), 202010%29,242NAnot evaluable0.0100.01.0relative treatment effectwww.metaEvidence.org2025-03-09 02:50 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 755 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons